Targeted inhibition of IL-23 via monoclonal antibodies against the p19 subunit—such as guselkumab, tildrakizumab, and risankizumab—has demonstrated substantial efficacy in treating moderate to severe plaque psoriasis (Kerschbaumer et al., 2024; Thomas et al., 2024). Here, IL23A is linked to psoriasis vulgaris.